1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Stockwatch: Yard sale drug development

 
• By Andy Smith

Investors have long memories. In the UK, generalist fund managers still speak in typically pejorative terms of the companies and drugs that have lost them money, the experience of which has deterred them from ever investing in the sector again. In the US however, either investors have shorter memories, are more forgiving, or are keen to reward failure with further investment as this week saw two drugs resurrected from the trash can to form the basis of new companies.

Investors have long memories. In the UK, generalist fund managers still speak in typically pejorative terms of the companies and drugs that have lost them money, the experience of which has deterred them from ever investing in the sector again. In the US however, either investors have shorter memories, are more forgiving, or are keen to reward failure with further investment as this week saw two drugs resurrected from the trash can to form the basis of new companies.

Durata Therapeutics this week amended its proposed IPO to raise about $75 million in order to enable the running of the phase III program for the glycopeptide antibiotic dalbavancin. Dalbavancin was formally the lead product of Vicuron, a company which completed three phase III studies and filed the NDA (scripintelligence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.